

# David M Livermore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112129/publications.pdf>

Version: 2024-02-01

121  
papers

17,728  
citations

28274

55  
h-index

18647

119  
g-index

121  
all docs

121  
docs citations

121  
times ranked

15619  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 597-602.   | 9.1  | 2,485     |
| 2  | Clinical epidemiology of the global expansion of <i>Klebsiella pneumoniae</i> carbapenemases. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 785-796.  | 9.1  | 1,328     |
| 3  | Multiple Mechanisms of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> : Our Worst Nightmare?. <i>Clinical Infectious Diseases</i> , 2002, 34, 634-640.  | 5.8  | 1,165     |
| 4  | Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 355-362.  | 9.1  | 1,045     |
| 5  | CTX-M: changing the face of ESBLs in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 165-174.   | 3.0  | 756       |
| 6  | Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. <i>FEMS Microbiology Reviews</i> , 2011, 35, 736-755.   | 8.6  | 728       |
| 7  | The role of ISAbal in expression of OXA carbapenemase genes in <i>Acinetobacter baumannii</i> . <i>FEMS Microbiology Letters</i> , 2006, 258, 72-77.   | 1.8  | 669       |
| 8  | Occurrence of carbapenemase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 153-163.                   | 9.1  | 522       |
| 9  | Persistence of sulphonamide resistance in <i>Escherichia coli</i> in the UK despite national prescribing restriction. <i>Lancet</i> , The, 2001, 357, 1325-1328.   | 13.7 | 416       |
| 10 | Molecular mechanisms disrupting porin expression in ertapenem-resistant <i>Klebsiella</i> and <i>Enterobacter</i> spp. clinical isolates from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 659-667.  | 3.0  | 390       |
| 11 | Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of <i>Acinetobacter baumannii</i> Mediated by the pmrAB Two-Component Regulatory System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3370-3379.  | 3.2  | 354       |
| 12 | Current Epidemiology and Growing Resistance of Gram-Negative Pathogens. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 128.  | 1.7  | 296       |
| 13 | What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 415-419.                             | 2.5  | 292       |
| 14 | Complete Nucleotide Sequences of Plasmids pEK204, pEK499, and pEK516, Encoding CTX-M Enzymes in Three Major <i>Escherichia coli</i> Lineages from the United Kingdom, All Belonging to the International O25:H4-ST131 Clone. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4472-4482. | 3.2  | 256       |
| 15 | Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iii2-iii78.  | 3.0  | 246       |
| 16 | Discovery research: the scientific challenge of finding new antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1941-1944.   | 3.0  | 240       |
| 17 | Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 390-394.   | 3.2  | 240       |
| 18 | Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. <i>Journal of Infection</i> , 2014, 68, 321-331.  | 3.3  | 223       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 87-102.   | 3.0 | 201       |
| 20 | Fourteen years in resistance. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 283-294.  | 2.5 | 197       |
| 21 | Activity of MK-7655 combined with imipenem against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2286-90.  | 3.0 | 196       |
| 22 | Nursing homes as a reservoir of extended-spectrum $\beta$ -lactamase (ESBL)-producing ciprofloxacin-resistant <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 635-641.  | 3.0 | 182       |
| 23 | Antibiotic resistance among clinical isolates of <i>Acinetobacter</i> in the UK, and in vitro evaluation of tigecycline (GAR-936). <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 479-487.   | 3.0 | 181       |
| 24 | Occurrence of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Clones at Multiple Hospitals in London and Southeast England. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3623-3627.   | 3.9 | 172       |
| 25 | Diverse Sequence Types of <i>Klebsiella pneumoniae</i> Contribute to the Dissemination of <i>bla</i> <sub>NDM-1</sub> in India, Sweden, and the United Kingdom. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2735-2738.                                      | 3.2 | 165       |
| 26 | Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2288-2294.   | 3.0 | 163       |
| 27 | Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2141-2148.  | 3.0 | 154       |
| 28 | UK epidemic <i>Escherichia coli</i> strains A-E, with CTX-M-15 $\beta$ -lactamase, all belong to the international O25:H4-ST131 clone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1241-1244.   | 3.0 | 151       |
| 29 | Extended-spectrum $\beta$ -lactamase-producing <i>Escherichia coli</i> in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1325-1335. | 9.1 | 150       |
| 30 | In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5324-5330.   | 3.2 | 142       |
| 31 | In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 300-311.  | 3.0 | 132       |
| 32 | Efflux Pumps, OprD Porin, AmpC $\beta$ -Lactamase, and Multiresistance in <i>Pseudomonas aeruginosa</i> Isolates from Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2219-2224.  | 3.2 | 130       |
| 33 | AdeABC-mediated efflux and tigecycline MICs for epidemic clones of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1589-1593.  | 3.0 | 129       |
| 34 | Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 762-768.                            | 9.1 | 127       |
| 35 | OP0595, a new diazabicyclooctane: mode of action as a serine $\beta$ -lactamase inhibitor, antibiotic and $\beta$ -lactam enhancer™. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2779-2786.   | 3.0 | 127       |
| 36 | Metallo- $\beta$ -Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .   | 3.2 | 127       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | In Vivo Development of Ertapenem Resistance in a Patient with Pneumonia Caused by <i>Klebsiella pneumoniae</i> with an Extended-Spectrum $\beta$ -Lactamase. <i>Clinical Infectious Diseases</i> , 2006, 42, e95-e98.                     | 5.8  | 126       |
| 38 | Arrival of <i>Klebsiella pneumoniae</i> producing KPC carbapenemase in the United Kingdom. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1261-1264.  | 3.0  | 126       |
| 39 | Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1569-1577.  | 3.0  | 125       |
| 40 | <i>In Vitro</i> Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3840-3844.   | 3.2  | 116       |
| 41 | In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1373-1385.   | 3.0  | 114       |
| 42 | Activity of ceftolozane/tazobactam against surveillance and "problem" Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> and non-fermenters from the British Isles. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2278-2289.    | 3.0  | 109       |
| 43 | Cephalosporinases associated with outer membrane vesicles released by <i>Bacteroides</i> spp. protect gut pathogens and commensals against $\beta$ -lactam antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 701-709. | 3.0  | 93        |
| 44 | Ciprofloxacin resistance in <i>Neisseria gonorrhoeae</i> in England and Wales in 2002. <i>Lancet</i> , The, 2003, 361, 1867-1869.   | 13.7 | 92        |
| 45 | OXA-1 $\beta$ -lactamase and non-susceptibility to penicillin/ $\beta$ -lactamase inhibitor combinations among ESBL-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 326-333.                 | 3.0  | 91        |
| 46 | Decline of EMRSA-16 amongst methicillin-resistant <i>Staphylococcus aureus</i> causing bacteraemias in the UK between 2001 and 2007. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 446-448.                                    | 3.0  | 86        |
| 47 | Activity of biapenem (RPX2003) combined with the boronate $\beta$ -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1825-1831.                       | 3.0  | 86        |
| 48 | Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2667-2674.                        | 3.0  | 83        |
| 49 | Dominance of international 'high-risk clones' among metallo- $\beta$ -lactamase-producing <i>Pseudomonas aeruginosa</i> in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 103-110.                                      | 3.0  | 81        |
| 50 | Cephalosporin resistance mechanisms in <i>Escherichia coli</i> isolated from raw chicken imported into the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2534-2537.  | 3.0  | 78        |
| 51 | Variation in the genetic environments of blaCTX-M-15 in <i>Escherichia coli</i> from the faeces of travellers returning to the United Kingdom. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1005-1012.                        | 3.0  | 76        |
| 52 | Activity of cephalosporin CXA-101 (FR264205) against <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> group strains and isolates. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 402-406.                  | 2.5  | 69        |
| 53 | Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus $\beta$ -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1972-1974.                                     | 3.0  | 69        |
| 54 | <i>In Vitro</i> Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .  | 3.2  | 65        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, ii41-ii54.   | 3.0 | 62        |
| 56 | NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1777-1784.  | 3.0 | 59        |
| 57 | Activity of ceftazidime/avibactam against problem Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> in the UK, 2015-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 648-657.   | 3.0 | 56        |
| 58 | Characterization of $\beta$ -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1354-1358.   | 3.0 | 55        |
| 59 | Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 953-960.  | 3.0 | 55        |
| 60 | Molecular epidemiology of fluoroquinolone-resistant ST131 <i>Escherichia coli</i> producing CTX-M extended-spectrum $\beta$ -lactamases in nursing homes in Belfast, UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 297-303.   | 3.0 | 54        |
| 61 | Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 1932-1934.  | 5.8 | 49        |
| 62 | Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and <i>Acinetobacter</i> spp. with carbapenemases, including NDM enzymes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 153-158.   | 3.0 | 48        |
| 63 | Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. <i>Clinical Infectious Diseases</i> , 2020, 71, 1776-1782. | 5.8 | 47        |
| 64 | Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Singapore Producing IMP-1 $\beta$ -Lactamase and Lacking an Outer Membrane Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1939-1940.   | 3.2 | 45        |
| 65 | Activity of OP0595/ $\beta$ -lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing $\beta$ -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3032-3041.   | 3.0 | 45        |
| 66 | Carbapenemases of <i>Chryseobacterium</i> ( <i>Flavobacterium</i> ) <i>meningosepticum</i> : Distribution of blaB and Characterization of a Novel Metallo- $\beta$ -Lactamase Gene, blaB3 , in the Type Strain, NCTC 10016. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1448-1452.                              | 3.2 | 40        |
| 67 | Detection of CTX-M-15 extended-spectrum $\beta$ -lactamase in the United Kingdom. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 528-529.  | 3.0 | 39        |
| 68 | Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. <i>Thorax</i> , 2022, 77, 1220-1228.   | 5.6 | 39        |
| 69 | Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic Stewardship. <i>Infection and Chemotherapy</i> , 2013, 45, 1.  | 2.3 | 38        |
| 70 | Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of <i>Enterobacter cloacae</i> during ciprofloxacin treatment. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 478-481.  | 2.5 | 36        |
| 71 | Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108 717 clinical isolates from primary, secondary and tertiary care patients in London. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3409-3422.                                       | 3.0 | 35        |
| 72 | Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with $\beta$ -Lactams against OP0595-Resistant Enterobacteriaceae Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 554-560.   | 3.2 | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework. <i>BMJ Quality and Safety</i> , 2022, 31, 199-210.   | 3.7 | 33        |
| 74 | Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2282. | 7.4 | 32        |
| 75 | In vitro activity of rifaximin against clinical isolates of <i>Escherichia coli</i> and other enteropathogenic bacteria isolated from travellers returning to the UK. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 431-437.                       | 2.5 | 31        |
| 76 | Activity of $\beta$ -lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 160-170.   | 3.0 | 29        |
| 77 | Doripenem: antimicrobial profile and clinical potential. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 455-458.   | 1.8 | 28        |
| 78 | Distribution of $\beta$ -lactamases in carbapenem-non-susceptible <i>Acinetobacter baumannii</i> in Riyadh, Saudi Arabia. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 17-21.   | 2.2 | 28        |
| 79 | Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1050-1056.                                      | 3.0 | 27        |
| 80 | Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 126-133.  | 3.0 | 26        |
| 81 | Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3336-3345.  | 3.0 | 26        |
| 82 | WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, <i>Pseudomonas</i> and <i>Acinetobacter</i> with class A, C and D $\beta$ -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1688-1695.                  | 3.0 | 24        |
| 83 | Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 279-285.                      | 3.0 | 23        |
| 84 | The 2018 Garrod Lecture: Preparing for the Black Swans of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2907-2915.   | 3.0 | 23        |
| 85 | Antibiotic resistance during and beyond COVID-19. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, i5-i16.  | 2.1 | 23        |
| 86 | Two widely disseminated strains of <i>Enterococcus faecalis</i> highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 711-714.   | 3.0 | 22        |
| 87 | Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2844-2853.   | 3.0 | 21        |
| 88 | KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1199-1206.  | 3.0 | 21        |
| 89 | Inherent colistin resistance in genogroups of the <i>Enterobacter cloacae</i> complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2452-2461.         | 3.0 | 20        |
| 90 | Variable susceptibility to piperacillin/tazobactam amongst <i>Klebsiella</i> spp. with extended-spectrum beta-lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 605-612.   | 3.0 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Of stewardship, motherhood and apple pie. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 319-322.   | 2.5 | 19        |
| 92  | The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 89.  | 1.6 | 19        |
| 93  | Strategies to overcome extended-spectrum $\beta$ -lactamases (ESBLs) and AmpC $\beta$ -lactamases in shigellae. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 405-409.   | 2.5 | 18        |
| 94  | Potential of imipenem by relebactam for <i>Pseudomonas aeruginosa</i> from bacteraemia and respiratory infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1940-1944.  | 3.0 | 18        |
| 95  | Etest $\hat{\text{A}}^{\circ}$ versus broth microdilution for ceftaroline MIC determination with <i>Staphylococcus aureus</i> : results from PREMIUM, a European multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 431-436.   | 3.0 | 17        |
| 96  | Activity of cefepime/zidebactam (WCK 5222) against $\hat{\text{A}}^{\circ}$ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1511-1522.  | 3.0 | 17        |
| 97  | INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care $\hat{\text{A}}^{\circ}$ study protocol for a multicentre randomised controlled trial. <i>Trials</i> , 2021, 22, 680. | 1.6 | 17        |
| 98  | SUSceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106574.   | 2.5 | 16        |
| 99  | A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study. <i>Antibiotics</i> , 2017, 6, 9.   | 3.7 | 15        |
| 100 | Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv265.  | 3.0 | 11        |
| 101 | Genetic environment of metallo- $\beta$ -lactamase genes in <i>Pseudomonas aeruginosa</i> isolates from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv263.  | 3.0 | 11        |
| 102 | Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK. <i>BJU International</i> , 2015, 116, 131-134.  | 2.5 | 11        |
| 103 | Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3239-3243.  | 3.0 | 11        |
| 104 | Selection and characterization of mutational resistance to aztreonam/avibactam in $\beta$ -lactamase-producing Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 98-111.   | 3.0 | 11        |
| 105 | Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106318.  | 2.5 | 9         |
| 106 | What's left in the cupboard? Older antimicrobials for treating gonorrhoea. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1215-1220.  | 3.0 | 8         |
| 107 | Replacement of <i>Enterococcus faecalis</i> by <i>Enterococcus faecium</i> as the predominant enterococcus in UK bacteraemias. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab185.  | 2.1 | 7         |
| 108 | <i>Pseudomonas aeruginosa</i> sequence type 357 with VEB extended-spectrum $\beta$ -lactamases in the UK: relatedness and resistance. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 301-302.   | 2.5 | 5         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. <i>European Urology Focus</i> , 2022, 8, 1483-1492.  | 3.1  | 5         |
| 110 | Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria. <i>Pharmaceutics</i> , 2021, 13, 2186.  | 4.5  | 5         |
| 111 | Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant <i>Escherichia coli</i> With Tigecycline Monotherapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz551.  | 0.9  | 4         |
| 112 | Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 131-134.   | 2.5  | 3         |
| 113 | Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .   | 3.2  | 3         |
| 114 | In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> isolates from the UK. <i>Access Microbiology</i> , 2020, 2, .   | 0.5  | 3         |
| 115 | AmpC hyperproduction in a <i>Cedexa davisae</i> implant-associated bone infection during treatment: a case report and therapeutic implications. <i>BMC Infectious Diseases</i> , 2022, 22, 33.  | 2.9  | 3         |
| 116 | COVID-19 vaccination and HIV-1 acquisition. <i>Lancet</i> , The, 2022, 399, e34-e35.  | 13.7 | 3         |
| 117 | Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to $\beta$ -lactamase type and enhancer effect, as tested by BSAC agar dilution. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , . | 3.0  | 3         |
| 118 | Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1822-1831.  | 3.0  | 1         |
| 119 | Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-110.                                  | 0.7  | 1         |
| 120 | Decreased susceptibility to cephalosporins among gonococci? – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 186-187.   | 9.1  | 0         |
| 121 | Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream <i>Escherichia coli</i> in a long-term surveillance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .  | 3.0  | 0         |